HUH? Dear WordPress......the (s)election is NOT over.
Complicit murderers aligned for a political scheme against President Trump.
Crony hacktivists masquerading as professionals.
You need to include all the hack journalists who just spouted the science and experts say. Experts is a word that means a democrat operative who we are quoting their bs but they do not have the conviction to put their name out. If they put their name out people would know them for the hacks they are.
bkmk
Now that the AMA thinks the election is over...
Kamala what’s her name has not given up her senate seat.
FAKE NEWS ALERT!!!
The AMA considered such a resolution, which is news, but defeated it.
Bump
is Neil Cavuto ever going to apologize on this, he was way out in front screaming how Trump was killing people talking about HCQ
However, on page 18 of a recent AMA memo, issued on October 30, (resolution 509, page 3) the organization officially reversed its stance on HCQ, stating that its potential for good currently may supersede the threat of any potentially harmful side effects.
Copy and paste the link and click reader view (at far left of the URL on the address bar) to avoid multitude of ads.
https://www.publishedreporter.com/2020/12/11/american-medical-association-rescinds-previous-statement-against-prescription-of-hydroxychloroquine-to-covid-19-patients/I
So let’s see...
- HCL really is useful
- Humper was under intensive investigation and it’s far bigger then anyone thought
- The vaccines were on their way as advised and are in fact in the process of being administered (doc friend of mine got his 1st shot today)
Seems like PDJT was right on pretty much everything.
When will the apologies start coming?
It really doesn’t matter how may people died. The important thing is that Trump is (they think!) gone.
By any means necessary means BY ANY MEANS NECESSARY, if the world economy crashes, if millions suffer avoidable death and misery, if Communist China imposes their system of suppression and crushing (literally) dissent on the entire planet, that’s a small price to pay.
They are quite, quite mad.
I don’t know what it will take to dispel this inaccurate story.
First, the proposed change was from a delegation for consideration by the AMA congress, not a statement from AMA.
Second, it didn’t claim AMA had erred regarding efficacy of HCQ, only that the AMA should not stand in the way of patient-doctor right to off-label use.
Third, the AMA rejected the resolution and will continue to pressure doctors not to prescribe HCQ for Covid.
Regardless, I am convinced that AMA is acting politically, not basing their position on history or on the worldwide clinical experience with HCQ regimens.
Accordingly, I have the components of the HCQ-Ax-Zn regimen ready to use at the first sign of infection.
It turns out the AMA’s committee Resolution A in the below information re HCQ/Zinc WAS NOT ADOPTED! AMA position is UNCHANGED.
Scroll down to Resolution A:
Earlier, I sent you information that the AMA had recommended physicians be permitted to prescribe off label combinations of drugs for CV 19 that are in common use. It was a committee recommendation. It was not approved. AMA is back to their original recommendation of “no”. The text that follows depicts the discussion.
Just when you think the AMA is acting rationally...and then....it’s the same old AMA.
RESOLUTION 509 – HYDROXYCHLOROQUINE AND
7 COMBINATION THERAPIES – OFF-LABEL USE
8
9 RECOMMENDATION A:
10
11 Resolution 509 not be adopted.
12
13 RECOMMENDATION B:
14
15 Policy H-120.988 be reaffirmed.
16
17 HOD ACTION: Policy H-120.988 reaffirmed.
18
19
20 RESOLVED, that our American Medical Association rescind its statement calling for
21 physicians to stop prescribing hydroxychloroquine and chloroquine until sufficient evidence
22 becomes available to conclusively illustrate that the harm associated with use outweighs
23 benefit early in the disease course. Implying that such treatment is inappropriate contradicts
24 AMA Policy H-120.988 that addresses off label prescriptions as appropriate in the judgement
25 of the prescribing physician; (New HOD Policy) and be it further
26
27 RESOLVED, that our AMA rescind its joint statement with the American Pharmacists
28 Association and American Society of Health System Pharmacists, and update it with a joint
29 statement notifying patients that further studies are ongoing to clarify any potential benefit of
30 hydroxychloroquine and combination therapies for the treatment of COVID-19; (New HOD
31 Policy) and be it further
32
33 RESOLVED, that our AMA reassure the patients whose physicians are prescribing
34 hydroxychloroquine and combination therapies for their early-stage COVID-19 diagnosis by
35 issuing an updated statement clarifying our support for a physician’s ability to prescribe an
36 FDA-approved medication for off label use, if it is in her/his best clinical judgement, with
37 specific reference to the use of hydroxychloroquine and combination therapies for the
38 treatment of the earliest stage of COVID-19; (New HOD Policy) and be it further
39
40 RESOLVED, that our AMA take the actions necessary to require local pharmacies to fill valid
41 prescriptions that are issued by physicians and consistent with AMA principles articulated n
42 AMA Policy H-120.988, including working with the American Pharmacists Association and
43 American Society of Health System Pharmacists. (New HOD Policy)
44
45 Your Reference Committee reviewed passionate and mixed testimony from both the online
46 testimony and in the live hearing on this resolution.
47
48 Your AMA Board of Trustees (BOT) provided testimony in opposition of this Resolution and
49 supportive of the AMA statement. The BOT noted that several commentors misconstrued the
50 language in the statement and outlined that it very clearly says, “Novel off-label use of FDA
Reference Committee E (November 2020 Meeting)
Page 16 of 18
1 approved medications is a matter for the physician’s or other prescriber’s professional
2 judgment” and also emphasized the need for physicians to rely on their professional judgment
3 and medical evidence for any potential COVID-19 treatment option. The statement further
4 notes that any use of these medications should be coordinated with a treating physician with
5 full understanding of the potential risks and benefits. The statement was accurate at the time
6 it was issued and took the best evidence available into account. The BOT, CSAPH, and the
7 majority of those who testified noted that while hydroxychloroquine has demonstrated benefits
8 for multiple chronic autoimmune and rheumatologic diseases, the benefit for treatment of
9 COVID-19, at the time of the statement, had not been established, and that the AMA should
10 base statements and policy on evidence and science. Many commentors, including the BOT
11 and CSAPH noted that since the release of the statement several well-designed studies have
12 failed to find benefit in the use of hydroxychloroquine for treatment of COVID-19 in multiple
13 settings. Several who testified also noted that it would be an embarrassment to the AMA and
14 call the credibility of the AMA into question to rescind a statement that was evidence-based
15 and accurate.
16
17 Those supportive of Resolution 509 noted that the statement was offensive to physicians and
18 could undermine the patient-physician relationship. Your Reference Committee understands,
19 and agrees with the need for physician autonomy, but also agrees with the BOT testimony
20 that the AMA statement does not infringe on physician autonomy and thus should not be
21 rescinded. Your Reference Committee feels that AMA Policy H-120.988, “Patient Access to
22 Treatments Prescribed by Their Physicians,” very clearly articulates the AMA’s strong support
23 for autonomous clinical decision-making authority of physicians. Therefore, your Reference
24 Committee recommends that Resolution 509 not be adopted and Policy H-120.988 be
25 reaffirmed.
26
27 H-120.988, “Patient Access to Treatments Prescribed by Their Physicians”
28 1. Our AMA confirms its strong support for the autonomous clinical decision-making
29 authority of a physician and that a physician may lawfully use an FDA approved
30 drug product or medical device for an off-label indication when such use is based
31 upon sound scientific evidence or sound medical opinion; and affirms the position
32 that, when the prescription of a drug or use of a device represents safe and
33 effective therapy, third party payers, including Medicare, should consider the
34 intervention as clinically appropriate medical care, irrespective of labeling, should
35 fulfill their obligation to their beneficiaries by covering such therapy, and be
36 required to cover appropriate ‘off-label’ uses of drugs on their formulary.
37 2. Our AMA strongly supports the important need for physicians to have access to
38 accurate and unbiased information about off-label uses of drugs and devices, while
39 ensuring that manufacturer-sponsored promotions remain under FDA regulation.
40 3. Our AMA supports the dissemination of generally available information about off-
41 label uses by manufacturers to physicians. Such information should be
42 independently derived, peer reviewed, scientifically sound, and truthful and not
43 misleading. The information should be provided in its entirety, not be edited, or
44 altered by the manufacturer, and be clearly distinguished and not appended to
45 manufacturer-sponsored materials. Such information may comprise journal
46 articles, books, book chapters, or clinical practice guidelines. Books or book
47 chapters should not focus on any particular drug. Dissemination of information by
48 manufacturers to physicians about off-label uses should be accompanied by the
49 approved product labeling and disclosures regarding the lack of FDA approval for
50 such uses, and disclosure of the source of any financial support or author financial
51 conflicts.
Reference Committee E (November 2020 Meeting)
Page 17 of 18
1 4. Physicians have the responsibility to interpret and put into context information
2 received from any source, including pharmaceutical manufacturers, before making
3 clinical decisions (e.g., prescribing a drug for an off-label use).
4 5. Our AMA strongly supports the addition to FDA-approved labeling those uses of
5 drugs for which safety and efficacy have been demonstrated.
6 6. Our AMA supports the continued authorization, implementation, and coordination
7 of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity
8 Act.
.
Fake news. Just a resolution. Defeated.
All deserve execution. They purposefully murdered mass numbers of people for political gain.
Election isn’t even close to being over...F-—Nut!
Leaving Mexico right now, with 40 HCQ tabs that I got OTC.
Screw the AMA and everyone else who killed tens of thousands for political or monetary reasons. I will do what is best for me and mine, period.